Pictet Asset Management Holding SA Sells 20,270 Shares of Medpace Holdings, Inc. $MEDP

Pictet Asset Management Holding SA decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 68.2% during the 4th quarter, HoldingsChannel reports. The fund owned 9,443 shares of the company’s stock after selling 20,270 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Medpace were worth $5,353,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Quent Capital LLC bought a new stake in Medpace in the 3rd quarter valued at approximately $25,000. Optiver Holding B.V. bought a new stake in Medpace in the 3rd quarter valued at approximately $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in Medpace in the 4th quarter valued at approximately $30,000. Quarry LP bought a new stake in Medpace in the 3rd quarter valued at approximately $35,000. Finally, Root Financial Partners LLC bought a new stake in Medpace in the 3rd quarter valued at approximately $38,000. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

NASDAQ:MEDP opened at $417.54 on Monday. The firm has a market capitalization of $11.92 billion, a price-to-earnings ratio of 26.24, a price-to-earnings-growth ratio of 2.12 and a beta of 1.19. Medpace Holdings, Inc. has a twelve month low of $284.10 and a twelve month high of $628.92. The stock’s 50 day moving average price is $468.91 and its two-hundred day moving average price is $532.96.

Medpace (NASDAQ:MEDP) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. The business had revenue of $706.60 million for the quarter, compared to analyst estimates of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm’s revenue was up 26.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts anticipate that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Analyst Ratings Changes

MEDP has been the topic of several recent analyst reports. Leerink Partners lowered their price target on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Truist Financial lowered their price target on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. BMO Capital Markets lowered their price target on Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research report on Friday, April 24th. Wall Street Zen lowered Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Royal Bank Of Canada lowered their price target on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus target price of $467.08.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.50% of the company’s stock.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Neutral Sentiment: Bares Capital trims its stake in Medpace, a portfolio move that may reflect manager rebalancing or concern about near-term risks. Bares Capital Trims Stake
• Negative Sentiment: A class action has been filed against Medpace and certain officers alleging violations of the federal securities laws for the period Apr 22, 2025–Feb 9, 2026; this formal filing increases legal exposure and investor uncertainty. Bronstein, Gewirtz & Grossman Class Action
• Negative Sentiment: Multiple plaintiff firms are actively soliciting lead plaintiffs and issuing investor alerts (Schall, Gross, BFA Law, Pomerantz, Rosen, Faruqi & Faruqi, Portnoy, Robbins, SueWallSt, Frank R. Cruz, Robbins LLP). The flurry of filings/solicitations heightens the probability of consolidated litigation, potential discovery, legal fees and settlement risk. Examples: Schall Law Firm Gross Law Firm BFA Law Pomerantz
• Negative Sentiment: Media coverage highlights that peers (Agios) posted strong results while reporting noted Medpace flagged rising cancellations—this operational disclosure appears to be the proximate cause of the stock weakness and underpins many litigation claims alleging the company misrepresented backlog/cancellation risks. Agios / Medpace Cancellations Coverage

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.